文献速递其他结缔组织病

CD40-CD154通路阻断抑制NOD/ShiLtJ小鼠干燥综合征模型中的异位淋巴结构及病理

Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren's syndrome.
PubMed 文献 · Ann Rheum Dis · 2019-03-22

该研究在NOD/ShiLtJ干燥综合征小鼠模型中检测CD40-CD154共刺激通路的作用,发现唾液腺存在CD40表达及通路激活证据;治疗性给予抗CD154抗体MR1可抑制CD40通路基因、唾液腺炎、异位淋巴结构形成和自身抗体产生,减少唾液腺抗体分泌细胞频率,但对AQP5表达影响极小。结论提示CD40-CD154相互作用在干燥综合征关键病理过程中起重要作用,临床阻断该通路可能有治疗益处。

要点

  • NOD/ShiLtJ小鼠唾液腺可检测到CD40表达及通路激活证据。
  • 抗CD154抗体MR1治疗抑制唾液腺炎、异位淋巴结构和自身抗体产生。
  • MR1减少唾液腺抗体分泌细胞频率,但对AQP5表达影响极小。

核心结论

  • CD40-CD154相互作用在干燥综合征小鼠模型的关键病理过程中起重要作用,临床阻断该共刺激通路可能对干燥综合征患者有治疗益处。

研究设计与样本

  • 研究采用NOD/ShiLtJ干燥综合征小鼠模型,通过免疫组化评估唾液腺白细胞浸润并分析唾液腺组织转录组数据,并在疾病样病变发作后给予抗CD154抗体MR1治疗。

主要发现

  • NOD小鼠唾液腺组织可检测到CD40表达及通路激活证据。
  • MR1治疗抑制CD40通路基因和唾液腺炎,抑制异位淋巴结构形成和自身抗体产生,并降低唾液腺抗体分泌细胞频率。
  • MR1对NOD/ShiLtJ小鼠唾液腺AQP5表达影响极小。

临床怎么用

  • 该小鼠模型结果提示CD40-CD154通路阻断可能作为干燥综合征的潜在治疗策略,但尚需临床研究验证。

局限性

  • 研究仅基于NOD/ShiLtJ小鼠模型,结论向人类干燥综合征的外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the role of CD40-CD154 costimulation and effects of therapeutic pathway blockade in the non-obese diabetic (NOD/ShiLtJ) model of Sjögren's syndrome (SS). METHODS: We assessed leucocyte infiltration in salivary glands (SGs) from NOD/ShiLtJ mice by immunohistochemistry and examined transcriptomics data of SG tissue from these animals for evidence of a CD40 pathway gene signature. Additionally, we dosed MR1 (anti-CD154 antibody) in NOD mice after the onset of SS-like disease and examined the effects of MR1 treatment on sialadenitis, autoantibody production, SG leucocyte infiltration, gene expression downstream of CD40 and acquaporin 5 (AQP5) expression. RESULTS: We could detect evidence of CD40 expression and pathway activation in SG tissue from NOD mice. Additionally, therapeutic treatment with MR1 suppressed CD40 pathway genes and sialadenitis, inhibited ectopic lymphoid structure formation and autoantibody production, as well as decreased the frequency of antibody-secreting cells in SGs but had minimal effects on AQP5 expression in NOD/ShiLtJ SGs. CONCLUSION: CD40-CD154 interactions play an important role in key pathological processes in a mouse model of SS, suggesting that blockade of this costimulatory pathway in the clinic may have beneficial therapeutic effects in patients suffering from this autoimmune exocrinopathy.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Wieczorek G, Bigaud M, Pfister S, et al. Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren's syndrome. Ann Rheum Dis. 2019. PMID: 30902822. doi:10.1136/annrheumdis-2018-213929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。